Results 161 to 170 of about 93,845 (280)

Polydrug fatal intoxication involving MDPHP: Detection and in silico investigation of multiple 3,4-methylenedioxy-derived designer drugs and their metabolites. [PDF]

J Anal Toxicol
Casati S, Ravelli A, Dei Cas M, Bergamaschi RF, Vanerio S, Sicuro L, Faraone C, Rossi M, Galante N, Mollica L, Roda G, Rota P, Battistini A.   +12 more
europepmc   +1 more source

The newest cathinone derivatives as designer drugs: an analytical and toxicological review. [PDF]

Forensic Toxicol, 2018
Majchrzak M, Celiński R, Kuś P, Kowalska T, Sajewicz M.   +4 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Sublethal Concentrations of 2C-I and 25I-NBOMe Designer Drugs Impact <i>Caenorhabditis elegans</i> Development and Reproductive Behavior. [PDF]

Int J Mol Sci
Gil-Martins E, Barbosa DJ, Cagide F, Remião F, Borges F, Silva R.   +5 more
europepmc   +1 more source

Detection and identification of designer drugs by nanoparticle-based NMR chemosensing. [PDF]

Chem Sci, 2018
Gabrielli L, Rosa-Gastaldo D, Salvia MV, Springhetti S, Rastrelli F, Mancin F.   +5 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Designer Drugs: A Synthetic Catastrophe. [PDF]

J Reward Defic Syndr, 2015
Fratantonio J, Andrade L, Febo M.
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

Designer drugs 2015: assessment and management. [PDF]

Addict Sci Clin Pract, 2015
Weaver MF, Hopper JA, Gunderson EW.
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source